3World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis[G].Geneva:WHO,2008(WHO/HTM/TB/2008.402). 被引量：1
4Jain A,Dixit P.Multidrug-resistant to extensively drug resistant tuberculosis:what is next?[J] Indian Academy of Science.J.Biosci,2008,33(4):605-616. 被引量：1
6WHO.Guidelines for the programmatic management of clrugresistant tuberculosis:Emergency update 2008[R/OL].http://whqlibdoc.who.int/publications/2008/978924154758/eng. 被引量：1
8Center for Disease Control and Prevention(CDC).Extensively drug-resistant tuberculosis-United States,1993-2006[J].MMWR Morb Mortal Wkly Rep,2007,56(11):250-253. 被引量：1
3World Health Organization/International Union Against Tuberculosis and Lung Diseases. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: WHO,1997.2-12. 被引量：1
4Murray CJL.Quantifying the burden of diseases: the technical basis for disability-adjusted life years.Bull World Health Organization,1994,72:429-445. 被引量：1
5Seung KJ,Bai GH,Kim SJ,et al.The treatment of tuberculosis in south Korea.Int J Tuberc Lung Dis,2003,7:912-919. 被引量：1
6Center for Disease Control and Prevention.TB elimination:now is the time.2002.Available from:URL:http://www.cdcnpin.org/scripts/tb/eliminate.asp. 被引量：1
7Ashokraj Y,Agrawal S,Varma MV,et al.Quality control of antituberculosis fixed-dose combination formulations in the global market:an in vitro study.Int J Tuberc Lung Dis,2004,8:1081-1088. 被引量：1
8Sterling TR,Lehmann HP,Frieden TR.Impact of DOTS compare with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths:decision analysis.BM J,2003,326:574. 被引量：1
9World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva:WHO,2006.361. 被引量：1
